跳至主要内容
临床试验/NCT06634836
NCT06634836撤回不适用

In-trial Qualitative Interviews to Explore the Impact of Gene Therapy in Hemophilia A & B

Pfizer0 个研究点目标入组 40 人开始时间: 2025年3月17日最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
发起方
Pfizer
入组人数
40
主要终点
Frequency of self-reported symptoms pre and post hemophilia gene therapy

研究概览

简要总结

The purpose of this study is to learn about experiences of patients with hemophilia A and B after taking gene therapy. The experiences of patients will be studied through online interviews.

This study is seeking participants who are:

  • part of the Pfizer's gene therapy clinical studies or
  • in the long-term follow up for these clinical programs. Participants will have one study visit at the clinic and one online interview. The planned duration for each participant will be 1 to 2 months. This covers the time from entering the study to end of the online interview.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Participation in the Pfizer's gene therapy clinical trials for Hemophilia A or B .
  • Participants will be one year or more post-gene therapy
  • Participants will be willing to provide written consent and will be willing to comply with the study requirements

排除标准

  • No exclusion criteria

结局指标

主要结局

Frequency of self-reported symptoms pre and post hemophilia gene therapy

时间窗: From date of dosing in the gene therapy clinical trial until the interview date, no less than 52 weeks.

Frequency of self-reported severity pre and post hemophilia gene therapy

时间窗: From date of dosing in the gene therapy clinical trial until the interview date, no less than 52 weeks.

Frequency of self-reported impacts pre and post hemophilia gene therapy

时间窗: From date of dosing in the gene therapy clinical trial until the interview date, no less than 52 weeks.

Change in the proportion of patients answering 5-point Likert scale questions about the burden of hemophilia on the participant's life pre-post gene therapy

时间窗: From date of dosing in the gene therapy clinical trial until the interview date, no less than 52 weeks.

次要结局

未报告次要终点

研究者

发起方
Pfizer
申办方类型
Industry
责任方
Sponsor

相似试验